Product Description
AZD1981 is a potent, fully reversible, functionally non-competitive antagonist of human CRTh2. AZD1981 blocks agonist-induced human eosinophil CD11b expression, shape change (including in whole blood), chemotaxis, basophil shape change and Th2-cell chemotaxis. AZD1981 is a weak inhibitor (>10muM) of CYP2C9, OATP1B1 and UGT1A1 as well as an inducer of CYP3A4 in vitro. (Sourced from: https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd1981.html)
Mechanisms of Action: CRTH2 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AstraZeneca
Company Location: Europe
Company Founding Year: 1999
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Chronic Obstructive Pulmonary Disease|Asthma|Urticaria
Phase 1: Healthy Volunteers|Asthma
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01311635 |
D9830C00020 | P1 |
Completed |
Healthy Volunteers |
2011-05-01 |
2019-03-19 |
Treatments |
|
NCT01254461 |
D9830C00016 | P1 |
Completed |
Healthy Volunteers |
2011-04-01 |
2019-03-19 |
||
NCT01265641 |
D9830C00011 | P1 |
Completed |
Asthma |
2011-04-01 |
2024-11-27 |
Primary Endpoints |
|
2010-021520-10 |
2010-021520-10 | P1 |
Completed |
Asthma |
2011-02-02 |
2025-06-29 |
Treatments |
|
NCT01196689 |
PEAK | P1 |
Completed |
Asthma |
2011-02-01 |
2019-03-19 |
Treatments |
|
NCT01199341 |
D9830C00017 | P1 |
Completed |
Healthy Volunteers |
2010-12-01 |
2019-03-19 |
Treatments |
|
NCT01110525 |
D9830C00015 | P1 |
Completed |
Healthy Volunteers |
2010-10-01 |
2019-03-19 |
Treatments |
|
NCT01058447 |
ADME | P1 |
Completed |
Healthy Volunteers |
2010-03-01 |
2019-03-19 |
Treatments |
|
NCT00698282 |
JSAD/JMAD | P1 |
Completed |
Healthy Volunteers |
2008-10-01 |
2019-03-18 |
Treatments |
|
NCT00918398 |
D9831C00003 | P1 |
Completed |
Healthy Volunteers |
None |
2019-03-18 |
Treatments |
|
NCT00859352 |
D9831C00008 | P1 |
Completed |
Healthy Volunteers |
None |
2019-03-18 |
Treatments |
|
NCT02031679 |
NA_00089252 | P2 |
Completed |
Urticaria |
2016-01-01 |
2019-03-20 |
Treatments |
|
2010-020407-73 |
2010-020407-73 | P2 |
Completed |
Asthma |
2012-02-16 |
2025-06-26 |
Treatments |
|
NCT01197794 |
Sweapea | P2 |
Completed |
Asthma |
2012-02-01 |
2019-03-19 |
Treatments |
|
2008-000311-15 |
2008-000311-15 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2009-07-20 |
2022-03-12 |
Treatments |
|
NCT00690482 |
Columbus | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2008-12-01 |
2019-03-18 |
Treatments |
|
2008-000340-13 |
2008-000340-13 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2008-02-27 |
2025-06-29 |
Treatments |
|
2006-001193-25 |
2006-001193-25 | P2 |
Completed |
Asthma |
2007-08-28 |
2022-03-12 |
Treatments |
|
NCT00758589 |
OLIVE | P2 |
Completed |
Asthma |
None |
2019-03-18 |
Treatments |
|
JapicCTI-111524 |
JapicCTI-111524 | P2 |
Completed |
Asthma |
None |
|||
NCT00766415 |
Biopsy | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
None |
2019-03-18 |